KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $42.3 million.

  • West Pharmaceutical Services' Depreciation & Amortization (CF) rose 763.36% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.0 million, marking a year-over-year increase of 1050.48%. This contributed to the annual value of $151.8 million for FY2024, which is 1353.78% up from last year.
  • As of Q3 2025, West Pharmaceutical Services' Depreciation & Amortization (CF) stood at $42.3 million, which was up 763.36% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Depreciation & Amortization (CF) ranged from a high of $42.3 million in Q3 2025 and a low of $27.7 million during Q2 2021
  • Its 5-year average for Depreciation & Amortization (CF) is $33.8 million, with a median of $33.6 million in 2023.
  • As far as peak fluctuations go, West Pharmaceutical Services' Depreciation & Amortization (CF) crashed by 681.11% in 2022, and later soared by 2041.52% in 2023.
  • Over the past 5 years, West Pharmaceutical Services' Depreciation & Amortization (CF) (Quarter) stood at $32.3 million in 2021, then decreased by 6.81% to $30.1 million in 2022, then grew by 14.95% to $34.6 million in 2023, then grew by 15.03% to $39.8 million in 2024, then grew by 6.28% to $42.3 million in 2025.
  • Its last three reported values are $42.3 million in Q3 2025, $40.8 million for Q2 2025, and $39.1 million during Q1 2025.